Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS
| Autor: | Thomas M. Hooton, Laura A. Koutsky, Sharon G. Hopkins, David H. Spach, Laura M. Newcomer, Susan E. Buskin |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male medicine.medical_specialty Immunology urologic and male genital diseases Acquired immunodeficiency syndrome (AIDS) Risk Factors Virology Internal medicine Trimethoprim Sulfamethoxazole Drug Combination Pneumonia Bacterial Immunology and Allergy Medicine Humans Retrospective Studies Acquired Immunodeficiency Syndrome AIDS-Related Opportunistic Infections business.industry Sulfamethoxazole Pneumonia Pneumocystis Respiratory disease Bacterial Infections Middle Aged bacterial infections and mycoses medicine.disease Trimethoprim female genital diseases and pregnancy complications Pneumonia Pneumocystis carinii Relative risk Etiology Female business medicine.drug |
| Zdroj: | Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 20(2) |
| ISSN: | 1077-9450 |
| Popis: | To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, Pneumocystis carinii pneumonia (PCP), and death in people with AIDS, we conducted a retrospective medical record review of 1078 persons who were observed for 3 years on average who attended nine outpatient facilities in Seattle, Washington between January 1990 and April 1996. We calculated relative risk estimates to measure the protective effect of TMP-SMX on the development of major bacterial illnesses, PCP, and death. Use of TMP-SMX decreased the risk of PCP (relative risk [RR] = 0.23; 95% confidence interval [CI], 0.14-0.36) and deaths not attributable to PCP (RR = 0.59; 95% CI, 0.47-0.73). Prevention of major bacterial illnesses of known etiology was of borderline significance (RR = 0.77; 95% CI, 0.57-1.05) and became statistically significant with the addition of patients with infections of unknown etiology (RR = 0.77; 95% CI 0.61-0.97). Use of TMP-SMX PCP prophylaxis significantly reduced the risks of death and of PCP and was associated with a trend toward reduced risk of major bacterial infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|